Dijon, France April 2, 2024, 10:30am CET — Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, announces progress on multiple fronts in its clinical development, registration and U.S. commercial strategy and reports its financial results for the year ending December 31, 2023.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner - July 4, 2025
- Air France-KLM initiates proceedings to take a majority stake in SAS - July 4, 2025
- Lerøy Seafood Group ASA: Trading update Q2 2025 - July 4, 2025
